Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: A simulation study

American Journal of Kidney Diseases

Volumn 64, Issue 6, 2014, Pages 867-879

  Greene, Tom ^a   Teng, Chia Chen ^a   Inker, Lesley A ^b   Redd, Andrew ^a   Ying, Jian ^a   Woodward, Mark ^c   Coresh, Josef ^d   Levey, Andrew S ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

chronic kidney disease (CKD); Clinical trials; eGFR trajectory; end stage renal disease (ESRD); estimated glomerular filtration rate (eGFR) decline; kidney disease outcome; kidney disease progression; kidney end point; renal end point; renal function; simulation; surrogate end point

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY BLOOD FLOW; LONG TERM CARE; MORTALITY; SAMPLE SIZE; SIMULATION; SURROGATE END POINT; VALIDITY; BIOASSAY; COMPUTER SIMULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; STANDARDS; TIME; UTILIZATION; VALIDATION STUDY;

COMPUTER SIMULATION; ENDPOINT DETERMINATION; GLOMERULAR FILTRATION RATE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 84910645074     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.08.019     Document Type: Article

References (22)

1. A.S. Levey, L.A. Inker, and K. Matsushita GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 6 2014 821 835
2. J. Coresh, T.C. Turin, and K. Matsushita Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 24 2014 2518 2531
3. H.J. Lambers Heerspink, H. Tighiouart, and Y. Sang GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials Am J Kidney Dis 64 6 2014 860 866
4. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 7 1996 605 613
5. M.M. Joffe, and T. Greene Related causal frameworks for surrogate outcomes Biometrics 65 2 2009 530 538
6. N. Stoycheff, K. Pandya, A. Okparavero, A. Schiff, A.S. Levey, and T. Greene Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset Nephrol Dial Transplant 26 2010 848 857
7. L.A. Inker, H.J. Lambers Heerspink, and H. Mondal GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials Am J Kidney Dis 64 6 2014 848 859
8. N.M. Laird, and J.H. Ware Random-effects models for longitudinal data Biometrics 38 1982 963 974
9. S. Klahr, A.S. Levey, and G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 330 13 1994 877 884
10. J.T. Wright Jr., G. Bakris, T. Greene and African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431
11. H.P. Hansen, P. Rossing, L. Tarnow, F.S. Nielsen, B. Jensen, and H.H. Parving Elevated GFR after withdrawal of chronic anti-hypertensive treatment in diabetic nephropathy [abstract] J Am Soc Nephrol 5 1994 378
12. A.J. Apperloo, D. deZeeuw, G. van Essen, and P. de Jong The initial GFR decline on anti-hypertensive treatment in long term interaction studies is reversible after withdrawal of treatment [abstract] J Am Soc Nephrol 5 1994 324
13. T. Greene A model for a proportional treatment effect on disease progression Biometrics 57 2 2001 354 360
14. A.S. Levey, T. Greene, and G.J. Beck Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD Study shown? J Am Soc Nephrol 10 11 1999 2426 2439
15. R.L. Prentice A log gamma model and its maximum likelihood estimation Biometrika 61 3 1974 539 544
16. L. Li, B.C. Astor, and J. Lewis Longitudinal progression trajectory of GFR among patients with CKD Am J Kidney Dis 59 4 2012 504 512
17. E.M. Chi, and G.C. Reinsel Models for longitudinal data with random effects and AR (1) errors J Am Stat Assoc 84 406 1989 452 459
18. J.H. Bauer, G.P. Reams, J. Hewett, and D. Klachko A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy Am J Kidney Dis 20 1992 443 457
19. R. Slataper, N. Vicknair, R. Sadler, and G.L. Bakris Comparative effects of different anti-hypertensive treatments of progression of diabetic renal disease Arch Intern Med 153 1993 973 980
20. G.L. Bakris, B.W. Barnhill, and R. Sadler Treatment of arterial hypertension in diabetic man: importance of therapeutic selection Kidney Int 41 1992 912 919
21. J.H. Bauer, and G.P. Reams Renal protection in essential hypertension: how do angiotensin converting enzyme inhibitors compare with calcium antagonists J Am Soc Nephrol 1 1990 580 587
22. I.H. Klein, A. Abrahams, T. van Ede, R.J. Hené, H.A. Koomans, and G. Ligtenberg Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects Transplantation 73 5 2002 732 736